CAC2 Childhood Cancer Community News Digest (March 20-26)

Assorted News from the Last Week:

Findings from a cohort study published in JAMA Network Open found that survivors of childhood cancer who lived in socioeconomically disadvantaged areas or had modifiable chronic health conditions were associated with an increased risk for death 5 years or more following the diagnosis of pediatric cancer.

Injectable methotrexate, cisplatin, and fluorouracil are all in shortage, according to the American Society of Health-System Pharmacists (ASHP).

The FDA has granted an orphan drug designation to FORE8394 for the treatment of primary brain and central nervous system (CNS) malignancies, according to an announcement from Fore Biotherapeutics.

Upcoming Webinars, Online Opportunities, and Meetings:

Free webinar for siblings of childhood cancer families sponsored by CAC2 Member Ryan’s Case for Smiles:  “What About Siblings?: Understanding and Supporting Siblings of Children with Illnesses and Injuries” on Wednesday April 12 at 1:00 pm EST. Click here for more information and to register.

Registration Closes on March 31!  The Alliance for Childhood Cancer is excited to announce that Action Days 2023 will return back to Washington, D.C. from April 24-25, 2023. Click here for more information and to register.

The Courageous Parent Network presents a webinar entitled Understanding and Addressing Pediatric Medical Trauma on April 12, at 8:00 pm ET,  Click here for more information.

Registration has opened for the CAC2 2023 Annual Summit, presented by Day One Biopharmaceuticals! This year’s conference takes place from noon, Monday, June 19 through 2:00 pm, Wednesday, June 21, 2023, in Atlanta, GA, at Children’s Healthcare of Atlanta Emory University.  Click here for more information and to register.

MIB Agents Osteosarcoma Alliance FACTOR 2023 Conference brings together the leading osteosarcoma researchers and clinicians, along with patient families and OsteoWarriors (survivors, patients and siblings of OsteoWarriors and OsteoAngels) to Make It Better for those battling this disease.  Click here for more information.

Take Action:

The 2023 Evan Lindberg & Erik Ludwinski College Scholarship Program is now accepting applications!  The program is open to high school seniors who are survivors of high-risk cancers or currently in treatment.  Students must be enrolled in a 4-year undergraduate institution and demonstrate a need for financial assistance. Three (3) $10,000 scholarships will be awarded. Applications are accepted from March 15 to May 1, with winners announced July 1.  Each winner will receive $2,500 in scholarship support their freshman year.  Funding will be renewed annually (for a total of $10,000 over 4 years), if eligibility requirements are maintained.  Please apply here: 2023 Childhood Cancer Survivor Scholarships — The EVAN Foundation.  Contact for more information:  info@theevanfoundation.org.

Buddy’s Place offers an 8-week support group each spring and fall. While children and teens engage in goal-oriented activities that are age-appropriate, parents and caregivers participate in a group focused on understanding children’s grief and how to better help the children work through it. The Spring 2023 Session will begin on March 21, 2023 and the Fall 2023 Session will begin on September 11, 2023.  Click here for more information.

The Communication Team at the Childhood Cancer Data Initiative is hoping to identify personal stories from the patient/caregiver/survivor perspective to feature in their monthly newsletter debuting next month.  Each month the CCDI progress update will include three stories of people in the childhood cancer community that either relate directly to childhood cancer data sharing or allow them to highlight a need that CCDI would help meet.  Please email Vickie at of you have a story or would like more information.

SUBSCRIBE

Sign up to receive a copy of CAC2's free childhood cancer news digest in your inbox each week.

Name(Required)
Email(Required)
This field is for validation purposes and should be left unchanged.